Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes
Posted: 23rd July 2013 | Posted by AdminMR
Annals of Allergy, Asthma & Immunology, Volume 107, Issue 4, Pages 289-299, October 2011, Authors:Linda Cox, MD; Robert E. Esch, PhD; Mark Corbett, MD; Cheryl Hankin, PhD; Michael Nelson, MD, PhD; Greg Plunkett, PhD
Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes
Currently, immunotherapy efficacy is determined with subjective assessments that rely on patient reporting, but this may change as health care reform evolves. It will likely become more important for US allergy/immunology practices to demonstrate immunotherapy comparative-effectiveness and report quality measures. Recent comparative-effectiveness studies have demonstrated the cost-effectiveness of immunotherapy compared with symptomatic drug treatment.